What We’re Reading: State Responses to Roe v Wade Leak; Metastatic Prostate Cancer Drug; Biogen CEO to Step Down
Half of US states are expected to restrict or ban abortion following the Supreme Court’s leaked draft majority opinion; Bayer’s darolutamide (Nubeqa) received FDA priority review as a treatment for metastatic hormone-sensitive prostate cancer; Biogen stops marketing its controversial Alzheimer drug as its CEO plans to step down.
US States Take Stand on Abortion Rights Following Supreme Court Leak
According to a state-by-state breakdown
FDA Grants Priority Review for Bayer’s Metastatic Prostate Cancer Drug
Bayer announced that the FDA accepted a supplemental new drug application and granted priority review for its oral androgen receptor inhibitor darolutamide (Nubeqa) in combination with docetaxel for treatment of metastatic hormone-sensitive prostate cancer.
Biogen Stops Marketing Alzheimer Drug as CEO Plans to Step Down
Biogen has announced plans to stop marketing its Alzheimer disease drug, aducanumab (Aduhelm), following its controversial approval, low sales, and Medicare’s extremely limited coverage of the drug. According to the biotechnology company, aducanumab created $2.8 million in revenue so far in 2022, combined with only $3 million in 2021. As
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025
- Eating Behaviors May Predict GLP-1 Therapy Success in Type 2 Diabetes
September 18th 2025